IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020.
Go here to read the rest:
Biomerica Reports Fiscal 2021 1st Quarter Financial Results
REDWOOD CITY, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020, the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to buy 150,000 shares of the Company’s common stock with a per share exercise price of $18.09, the closing trading price on the grant date, and 10,000 restricted stock units.
Continue reading here:
Coherus BioSciences Announces New Employment Inducement Grants
Orphazyme A/SCompany announcement No. 66/2020 Company Registration No. 32266355
Go here to see the original:
Stabilization measures taken
VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.
See original here:
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients –
DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.
Excerpt from:
Eton Pharmaceuticals Announces Closing of Public Offering
As flu season approaches and scientists continue to work on a vaccine for COVID-19, Andrea Amalfitano, dean of the College of Osteopathic Medicine and Osteopathic Heritage Foundation Endowed Professor of Pediatrics, Microbiology and Molecular Genetics, uses his expertise to shed light on how vaccines work and the process for creating new ones. The first of this two-part series addresses general questions about vaccines. The second part will address development of the COVID-19 vaccine.
How do vaccines work?
Vaccines work by introducing specific sub-portions, or antigens, of a desired target, like COVID-19, to the immune system in a manner that is safe and results in a training of the immune system should a vaccine be exposed to COVID-19 naturally.The vaccinated individual will be able to ramp up an immune response that eliminates the COVID-19 much more rapidly than someone who was not vaccinated, thereby minimizing or completely preventing illness.
Our laboratories previously developed, for example, a vaccine platform for use against a variety of targets. This platform was created by genetically engineering a common cold virus to present antigens safely to the immune system. This unique vaccine platform has been safely used in hundreds of clinical trial participants targeting their cancers, and that safety record has allowed researchers to now test the platforms ability to induce beneficial immunity against the COVID-19 virus in human subjects as part of an FDA-approved Phase I clinical trial.
Confirming safety is key, and at this time it is more critical than ever that FDA regulations are maintained and followed, as these will help confirm that an approved vaccine is both effective and safe.Suspending FDA regulations at this crucial time would be the last thing I would recommend, for example, to hasten the approval of any potential COVID-19 vaccine.Suspending FDA oversight would undermine the trust the public would have in any other vaccine, therapeutic, test or other medical device subsequently approved by the FDA.
We hear a lot about the fast-tracking of a coronavirus vaccine. What is the usual time frame for creating a new vaccine?
Andrea Amalfitano, dean of the College of Osteopathic Medicine and Osteopathic Heritage Foundation Endowed Professor of Pediatrics, Microbiology and Molecular Genetics.
In my experience as a clinician/scientist who has developed new vaccine technologies for various purposes, the track typically is multiple years. Fast-tracking is not the typical term applied to vaccines, as the brunt of the time required to get a new vaccine approved is devoted to confirming the vaccine can be scaled up consistently and also has no untoward side-effects, especially when it is planned to be administered to potentially millions of people.
Given that, the annual flu vaccine is what I would consider a fast-tracked vaccine, as it is essentially a novel vaccine every year. The reasons it can be fast-tracked are: 1) the long-standing safety record (decades) of developing and producing flu vaccines using tried and true scale-up methods, 2) long-standing blood tests that consistently measure, and then correlate the amount of anti-flu antibodies generated by each annual flu vaccine with ultimate potential for efficacy.
What are the steps or phases of researching a new vaccine?
Typically, any new drug, vaccine or other form of medical therapeutic or device goes through three phases of clinical trials prior to receiving approval for generalized usage. Phase I studies typically involve dose testing and safety studies in normal human volunteers, as appropriate. Phase II studies involve using optimal doses of the new drug or vaccine in those potentially benefitting from the therapeutic, for example, a new drug to treat high blood pressure being evaluated in patients with high blood pressure. For flu vaccines, this phase would attempt to note how many anti-flu antibodies are produced by the potential new vaccine, and if these antibody levels are above the known thresholds required to have a good vaccine. Phase III studies typically involve testing the new therapeutic in trial subjects as compared to use of currently available therapeutics for the same disease indication to verify it is an improvement.
For flu vaccines, and more specifically COVID-19-specific vaccines, this phase may include asking clinical trial participants to receive a potential COVID-19 vaccine and monitor the rate of COVID-19 infection by these vaccine recipients over time. If the COVID-19 vaccine is good, those who receive the potential vaccine should have a much lower rate of acquiring COVID-19 infection than those trial participants who receive a placebo vaccine.
What are the risks associated with getting a new vaccine?
Vaccines are some of, if not the safest, types of medications doctors can provide to their patients. In fact, if you look back through time, beyond clean water, vaccines have saved more lives and decreased morbidity of the human race more so than any other medicine.
Risks can occur, as with anything administered to a human even excess water consumption can be dangerous to humans. Clinical trials in hundreds or thousands of trial participants serve to identify potential side effects. Furthermore, many times the FDA will also add Phase IV studies, even after a new therapeutic or vaccine is approved, typically to monitor for very low-frequency side effects not identified in prior clinical trials.
Do vaccines have to be kept at a certain temperature to be effective?
This depends on the type of vaccine platform. Some can be dehydrated and/or delivered as an oral pill, while others may require refrigeration at specific temperatures to maintain viability. It is not clear what these viability requirements will be of the several potential COVID-19 vaccines currently being tested.
Obviously, this also has to be a consideration in regard to scalability. For example, if a vaccine can be delivered at room temperature and remain effective as an orally ingestiblepill or tablet, this vaccine will be much more likely to succeed, versus a different vaccine that requires refrigeration until the time of a required administration.
Originally posted here:
Ask the expert: How vaccines are created - MSUToday
As the Jonas Salk Chair for Vaccine Research and professor of microbiology and molecular genetics at the University of Pittsburgh, Paul Duprex has been leading the local effort to create candidate vaccines for COVID-19.
In March, he joined an international team of scientists in using the tried and true measles vaccinea weakened form of the virus Duprex has been studying for decadesas the basis for a new candidate vaccine against SARS-CoV-2. Phase 1 testing began in August.
More recently, Duprex joined forces with the massive global vaccine maker Serum Institute of India, which already produces vaccines for two-thirds of the worlds children, to manufacture a similar measles-based SARS-CoV-2 candidate vaccine developed solely at Pitt.
On Oct. 15 from 10 to 11:30 a.m. ET, Duprex will sit on a panel with vaccine experts from March of Dimes, Johns Hopkins, CDC Foundation and Pitt for a discussion about the challenges that lay ahead. The event is free and open to the public.Attendees must register at the Wilson Center website.
UPMC science writer Erin Hare caught up with Duprex in the Center for Vaccine Research, where he serves as director.
Think of a telephone. A telephone is very different in the 1960s compared to the cell phone that you carry in your pocket today. So, just imagine the same analogy and apply that to vaccines.
We can make vaccines in new ways. The toolkit is enormously large now, compared to what it was way back when. That doesn't mean that we don't do the same types of vaccines that were made in the 1960syes, that's part of the portfolio of vaccines, but there are many more vaccines available.
For instance, we can genetically engineer viruses. We can make one virus look like another virus. Or, we can take bits of genetic material and not even introduce proteins, which are normally recognized by the immune system. We can introduce the RNA, which makes the protein, which then is recognized by the immune system.
That's just examples of new ways to think about new vaccines, 65 years on.
One of the advantages is that we have studied coronaviruses for many years. So, we understand a bit about which parts of the coronavirus can be used to make a good immune response.
The other thing which is interesting about coronaviruses is they're really big viruses, and they have the ability to correct mistakes whenever they replicate, so any mutation gets fixed straight away. That's good for us because that means the virus doesn't change much the way some other viruses do.
Like, for example, influenza. Influenza mixes it up all the time. HIV mixes it up all the time. But because SARS-CoV-2 has this drive to keep itself the same, that means the likelihood of changing is less. Plus, the virus just has one genetic segment, so it's not like influenza. So, instead of shuffling a pack of cardsthe genetic material of influenzaSARS-CoV-2 can just play around with one sequence.
So those are all good things for us.
Hard things for us? Well, it's a brand-new virus. So, we still have to understand this relatively young virus. We have to understand a lot more about the biology of it. And, of course, the world is working hard on understanding the biology of SARS-CoV-2.
We need so many because the first vaccine may not always be the best vaccine. It may work, but it might not work as efficiently as some of the other ones, which just take a bit longer to bring through the pipeline of development.
So, it's the same as that old analogy: You shouldn't keep all of your eggs in one basket. It's good to have multiple baskets for your eggs. And it's pretty good to have multiple approaches to deal with a virus that's rather new. The other part of having multiple approaches is we just don't know how long the immune response will last. And therefore we can't assume too much until we have the data.
So, it's all driven by science. Science is creative. People are creative. People come up with many ways to get to the same end point, and that's why we need lots of different sorts of vaccines.
Well, I think one of the things that gives me hope is there are a lot of individuals working on the problem. The world is focusedthe virology community, the immunology community and many other disciplinesare laser focused on solving this problem. People have developed vaccines in the past. So, that gives me hope. But also what we have to remember is vaccines are not easy.
The average time to make a vaccine is 10 and a half years. And if you think about HIV, it pulls that average way up, because 36 years after identifying that virus, we still don't have a vaccine. So therefore vaccines are hard, but vaccines have led to the eradication of infectious diseases, and vaccines have done so much for human health. They consistently deliver, they consistently live up to their expectations, and they have delivered so many people who otherwise would not be here because vaccines actually work.
So, what gives me hope? Vaccines work.
First and foremost, I'm sympathetic to individuals who are trying their best to understand something which is familiar to scientiststhe process of vaccine developmentbut very foreign to the general public. No vaccine has ever been developed under the microscope like these candidate vaccines for SARS-CoV-2.
We also get our news from many different sources. We have social media, we have regular mediawe have this tsunami of information. And that's what makes it really hard for the public to weed through, because not all of that information is equivalent.
So, what's important is to get information from verified, validated, sound sourcesto look at the evidence produced by science. And the evidence says that vaccines work. That does not mean that vaccines work perfectly. Sometimes the influenza vaccine's great, sometimes in one particular year, for whatever reason, it just doesn't work as well. But we don't undermine all the vaccines because we do not get to perfection.
And we do realize that there are side effects, adverse events that happen. And that's why it's really important as we do vaccine development, clinical trials in the here and now, that we use all of the standard approaches in phase 1, phase 2, phase 3 clinical trials, to understand any potential effects, whatever that could be. And we only license safe, efficacious and life-giving vaccines.
What you also have to remember is these companies do much more than make a coronavirus vaccine. Some of them have made vaccines for many years. Some of them have never made a vaccine at all. So, there's an example of why I could be sympathetic and understand the population looking at it and thinking we're going to license something that has never been used before. But remember that these companies have reputations, they have other products, they have history, they have a brand, they are known and it's very unlikely a private company will throw all of that reputation in the air just to be first with unsafe, untested, non-satisfactory coronavirus vaccine.
Vaccines are not just produced and marketed and sold without a lot of care and a lot of attention to how they are made, tested and licensed.
This interview has been edited for length and clarity.
View post:
Q&A: Paul Duprex on the Promise of a COVID-19 Vaccine - UPJ Athletics
Like every Thursday Iker Jimnez sought answers to the mysteries about the coronavirus in a new installment of COVID Report. In this case, addressed the genetic key to the disease to try to find out if they exist people with more predisposition than others to be infected.
As in previous programs, surrounded himself with prestigious experts They showed their knowledge on the subject. The first to intervene was Paul bastard, pediatrician at the Necker Hospital in Paris and co-author of the latest study on interferons.
15% of patients with severe forms of COVID have a genetic and immunological susceptibility to make a serious form because they cannot defend themselves well because of a defect in interferon. The type I it is the most famous antiviral molecule and it is the first most useful to fight viruses, not only against the coronavirus, but against everyone. When the virus comes into contact with the cells of the body, they recognize it and there is like an alarm signal, which is the one that induces the production of type I interferon and we have found that the patients who have these autoantibodies were older and almost all, 94% were men. That may explain part of why it affects men and older people more, Bastard said.
He subsequently intervened Salvador Macip, specialist in Molecular Genetics and researcher at the University of Leicester, who stated that one of the great mysteries of this virus even now is what type of immunity it provokes: if you get infected, how your body reacts and why some people react better or worse than others. This it depends a lot on genes and factors that we do not know right now, we cant predict. Why are 10% of people going to have such an aggressive response? We have to look for it and understand it, but we do not know the immune reaction. We do not know why there are people who can be reinfected and it seems proven that a certain part of the population can be infected more than once. Why? It is one of the unknowns that must be answered And I dont think well do it anytime soon. It is a very complicated subject and will have to be studied even in years.
Csar Carballo, emergency assistant at the Ramn y Cajal University Hospital, assured that when the pandemic began the vast majority of patients were men. Although sometimes they came some young people who arrived very badly and there was something that we did not explain, which led us to think that there was something we did not know about the disease. You were left wondering what happened to these patients, who were 10-15%.
Carmen Chamber, Secretary General of the Spanish Immunology Society, confirmed that the figures leave no room for doubt. When we see series of mild COVID, there are 28% of men, in the severe it rises to 75% and in the study by Paul Bastard there is talk of 95%. But it is also important for people to know that in 85% of cases, the immune system of people can with the virus. In a wide range of cases it is not known that it has been had.
Miguel Pita, an expert in Genetics and Cell Biology at the Autonomous University of Madrid, stated that genetics always have something to sayeven when we least expect it. Some of them suddenly faced with a disease and make you more or less prepared, and it can even be random. We are detecting more and more elements that they make the prognosis better or worse due to small changes in the genetic material.
It will take time to have the answer, but Nowadays, patients are selected who have had a bad time with those who have not. Those are compared thousands of DNA to see what is different. Results that show that on chromosome 3 there is a region that has genes involved in the matter related to the lung. Now we have to investigate what happens there. You have to be cautious, because they are very early results added the specialist.
Alfredo Corell, Professor of Immunology at the University of Valladolid, member of the board of directors of the Spanish Society of Immunology and scientific disseminator, highlighted the importance of interferon: There are many types and it is so called because interferes so that the virus does not infect so easily. It is produced by cells of the immune system and signals cells with receptors. These signs They help the lung, protect the epithelia, the organism and send signals so that the immune response is lowered. All this together favors the action of interferon.
Although for Camera, interferons explain 10% of severe cases. When there are things that it only justifies a percentage, we are concerned. But its the first step forward we can give .
In a similar vein, Pita expressed himself, emphasizing that it is still early. Lung things, receptor genetics, etc. will be seen. Genetics can explain up to 50% of the variability in the form of prognosis from the patients. These interferon genes are not a single gene: it has been seen people who make anti-interferon antibodies and people who have trouble making interferon. We go really fast but we want to go faster than science allows us .
Pita recalled that it was one of the first results they tried to associate with prognosis of the illness. From the beginning they were very modest, but it could not be stated that it was a determining factor. We are on the verge of seeing more important things. Blood group may influence, but it is less decisive than diabetes or the gender of each person .
Chamber explained that the immune system has two lines defense: a quick and innate first that can beat COVID without leaving a signal in our blood and it is where type I interferon participates; there are a second, which is the adaptive, and its where T lymphocytes, antibodies, etc. go. and leave memory, with which we do the serological tests to know if we have passed the disease or not .
Therefore, Pita emphasized that If you dont have antibodies, it tells you very little. You are not even protected against reinfection, with which deep down it doesnt matter.
Pita gave several brushstrokes on some characteristics of the virus: We are focusing on the cases in which the genetic system goes wrong. But the virus has its own history. Muta pocor. That is good compared to other viruses, and if it were more mutant, it would be more difficult to find a vaccine. But between being not very aggressive and mutating little, we are not in the worst possible situation to be a pandemic. The strength of this virus is that it is very contagious, but many people are asymptomatic or have mild symptoms. If I put you on a bed, it would be less contagious.
More:
Iker Jimnez addresses the genetic code in COVID Report - Pledge Times
Healthcare systems across the world have always been under pressure; the pandemic simply multiplied it. It has also made the pre-existing challenges of healthcare systems visible to everyone. It has come to light that during the tough times, healthcare professionals were under-equipped, underpaid, and overworked.
While these conditions vary from one country to another, this has paved the way for the potential digitalisation of the healthcare services. It wont be an exaggeration to say that the COVID-19 crisis has boosted both the requirement and interest in such innovative solutions. Eventually, there is a high demand than ever before for ehealth or digital health. This has led to a rise in the relevant verticals including telehealth, mhealth, and health analytics.
These are the top global tech PR agencies you should absolutely check out in 2020
As per a report, the global digital health market is estimated to reach $511B (nearly 435B) by 2026, which is an impressive yearly growth rate of 26%. While markets such as the US and China are leading the digitalisation of health systems, other markets have picked up the pace now.
Talking about Germany, it is one of the leading startup scenes and Berlin remains the main focus of the German startup scene. Given that the report cites that the annual public health spending of Germany is $330B (nearly 281B), here we have listed the top healthtech startups in Cologne that are worth your attention right now as sourced from Dealroom.
Founder/s: David HennFounded year: 2016Funding: 25.6M
Cannamedical imports medical cannabis products and sells them to pharmacies and clinical facilities. It ensures medical care for patients and improves their quality of life. The Cannamedical portfolio includes cannabis varieties, medical marijuana grinders, cannabinoid oil, and more to treat ailments such as chronic pain and cancer.
Founder/s: Nicole Faust, Gudrun Schiedner, Wolfgang KintzelFounded year: 2001Funding: 19.4M
CEVEC Pharmaceuticals provides cell technology for the manufacturing of bio-therapeutics from R&D to manufacturing scale. Its product portfolio comprises platform technologies for gene therapy viral sectors, vaccines, and complex recombinant proteins. CEVEC offers a solution for large-scale production of AAV vectors using producer cell lines with all essential components that are integrated into the cell. Recently, the company launched the patent-protected ELEVECTA platform, which is a new and scalable production platform for AAV gene therapy vectors.
Founder/s: Frank Beyer, Gereon LillFounded year: 2016Funding: 2.6M
Fasciotens is a medical tech startup that works on new devices that make it easier to close the abdominal wall and increase the possibility of survival in ill patients. This solution is an external device, which maintains the abdominal wall in a state of tension and increases the intra-abdominal volume. With early abdominal closure, there is decreased mortality, reduced duration of intensive care treatment, and minimised hospital costs.
Founder/s: Hans-Peter DeignerFounded year: 2010Funding: 5.4M
InfanDx develops a new generation of diagnostic tests for the care of neonates. It focuses on the early identification of newborns suffering from critical oxygen supply deficit during birth termed Asphyxia), which is a major cause for brain injury often followed by life long disabilitation. It requires very early application after birth, and currently, theres no test system available to meet this crucial demand. InfanDx closes this diagnostic gap by carrying such a test system through clinical development until it is available for use in the hospital.
Founder/s: Thomas LisowskyFounded year: 2005Funding: 630K
multiBIND biotec develops solutions for disinfection and decontamination. Its technologies bioDECONT and bioCLEAN are not toxic and are free from hazardous chemicals and solvents. The company is involved in the development of technologies, products, and patents related to operations in molecular genetics and biomedicine.
Founder/s: Christoph von Dellingshausen, Donata von Dellingshausen, Nils von DellingshausenFounded year: 2012Funding: NA
BetterDoc operates with the vision to enable patients to get the best possible medical treatment for their health problems. Its data analytics platform aggregates all kinds of quality data from the health system and measures outcomes with patient-reported outcomes (PROs). This way, the company routes patients to the right doctors and getsget the best possible second medical opinion, treatment, or surgery. The BetterDoc service works with leading German health insurance companies for their customers.
Founder/s: Marc Ebinger, Robert HolzFounded year: 2016Funding: NA
Rimasys is a medtech company. The companys mission is to reinvent surgical education and enables medical science, academic, and the healthcare industry to develop and perform better implants, operations, and therapies. It improves patient outcomes at relatively lower costs. Furthermore, Rimasys provides holistic educational concepts for clinics, surgeons, and medtech companies complemented by 3D printing and virtual reality.
Founder/s: Carlos z Martnez, Samuel JellardFounded year: 2019Funding: 90K
Mane Biotech has developed regenerative medicine through stem-cell technology. The company has developed a wearable device for aiding in hair regrowth and delaying hair loss. The device stimulates tissues to accelerate the bodys own mechanism to regenerate hair. The potential of stem-cell driven regeneration is beyond comprehension and Mane Biotech is specialising in this aspect.
Founder/s: Andreas Schmidt, Dieter TrauFounded year: 2010Funding: 11.3M
AYOXXA is a biotech company commercialising innovative technology developed at the National University of Singapore (NUS). AYOXXAs patented technology platform is producing a new generation of biochips, which merges biology with IT. This allows the biochip to accumulate large numbers of applications measuring multiple protein markers for cancer, allergies, cardiovascular, and infectious diseases, in a single test.
Stock photo from S.Borisov/Shutterstock
See original here:
9 innovative Cologne-based healthtech startups to watch out for in 2020 - Silicon Canals
An influential Rare Disease Genetic Testing Market report carries out an evaluation of the growth rate and the market value of Rare Disease Genetic Testing industry based on market dynamics and growth inducing factors. Thorough market analysis covered in this report by skilled experts gives every bit of knowledge which is imperative to design and align with current market scenarios. This market research report is one-stop archive for in-depth knowledge of market analytics aggregated by a broad rundown of distributors from over the globe. Moreover, for the businesses, it is the most important to get knowhow of consumers demands, preferences, attitudes and their changing tastes about the specific product which can be studied via this winning Rare Disease Genetic Testing Market report.
Rare disease genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.30% in the above-mentioned forecast period. The increase in the facilities for patients affected by rare diseases has been directly impacting the growth of rare disease genetic testing market.
Get Free Sample Copy of the Report to understand the structure of the complete report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rare-disease-genetic-testing-market
Increasing need for an accurate and appropriate diagnosis for rare conditionsis expected to have a significant impact on the rare disease genetic testing market. Other impactful reasons for the market growth are rise in the number of available registries, rising prevalence of rare disorders along with wide-ranging investments in the diagnosis of rare disorders. On the other hand, the growing number of patients undergoingdisease testingand rising government assistance will further boost various new opportunities that will lead to the growth of the rare disease genetic testing market in the forecast period of 2020 to 2027.
Lack of regulatory framework in emerging economies associated with dearth of trained healthcare personnel is acting as major restraints to the growth of the rare disease genetic testing market in the above mentioned forecast period.
This rare disease genetic testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on rare disease genetic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Rare Disease Genetic Testing Market Country Level Analysis:
The countries covered in the Rare Disease Genetic Testing Market report are U.S., Canada, Mexico in North America, Germany, Poland, Ireland, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Chile, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Egypt, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Check Table of Contents of This Report @ https://www.databridgemarketresearch.com/toc/?dbmr=global-rare-disease-genetic-testing-market
Leading Rare Disease Genetic Testing manufacturers/companies operating at both regional and global levels:
Quest Diagnostics, Inc., Centogene N.V., Eurofins Scientific, Strand Life Sciences, Ambry Genetics, PerkinElmer, Inc., Macrogen, Inc., Baylor Genetics, Color, Health Network Laboratories, L.P., Preventiongenetics, Progenity, Inc., Invitae Corporation, 3billion, Inc., Arup Laboratories, Coopersurgical, Inc., Fulgent Genetics, Myriad Genetics, Inc., Laboratory Corporation Of America Holdings and Opko Health, Inc., among other domestic and global players.
GlobalRare Disease Genetic TestingMarket Scope and Market Size
Rare disease genetic testing market is segmented on the basis of disease type, technology, specialty and end use. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-rare-disease-genetic-testing-market
Key points of the report
Reasons for purchasing this Report
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates.
Contact Us:
Data Bridge Market Research
Tel: +18883872818
corporatesales@databridgemarketresearch.com
Follow this link:
Rare Disease Genetic Testing Market To Account To Grow At A CAGR Of 8.30% In The Forecast Period Of 2020 To 2027 | Major Giants Quest Diagnostics,...
COLUMBIA COUNTY
Local veterinarian Dr. Linsay Barnes saw a lack of diversity in the veterinary medicine field early in her career.
I was the only African American and the only African American female in my class, Barnes said.
In vet school she was the only minority in a class of 92 students.
This is a field for all. It just hasnt been represented that way, but it is a field for all, Barnes said.
The lack of diversity in the field led Dr. Ian Scholer, a veterinarian at Hill Top Animal Hospital in Augusta, and his wife, a teacher, to want to increase diversity in the veterinary industry.
Their organization Vets of all Colors partners with schools, in hopes of giving students an opportunity to know more about veterinary medicine and provide scholarship opportunities.
Kendra Collins is in the program, she says its a chance to see more students that look like her pursue vet medicine as a career.
There isnt a lot of African Americans in this profession so I guess it can be a little bit intimidating, but with more people it seems better and more welcoming, Collins said.
Opening doors for minorities and getting the money to help them achieve their dreams is the highest priority.
If were able to get some funding out to help these students move into that field then thats wonderful, Barnes said.
For more information on the scholarships and how to apply visit VetsofallColors.org
Excerpt from:
Local veterinarians aim to increase diversity in the field - WJBF-TV
Several veterinary organizations and associations released statements in recent months in support of diversity, equity, and inclusion as well as in response to the recent killings and shootings of Black individuals by police, including George Floyd, Jacob Blake, and Breonna Taylor, among many others, and the Black Lives Matter movement.
Since then, several organizations have transformed those statements into action.
The AVMA was working to establish a diversity, equity, and inclusion commission as of press time in early October. The Association is collaborating with key stakeholders to build a strategy and identify goals related to diversity, equity, and inclusion in the veterinary profession.
The AVMA also is in the process of hiring an outside consultant to support and advance its DEI initiatives. This summer, the AVMA created a new websiteto help members more easily access the organizations resources and policies regarding DEI. And in August, the American Veterinary Medical Foundation joined Hills Pet Nutrition in endowing a new scholarship program for veterinary students at Tuskegee University, which is a historically Black university.
Your courage will inspire action. This conversation should not end here. This is not a moment. This is a movement to change society.
Dr. Ruby Perry, dean, Tuskegee University College of Veterinary Medicine
The Association of American Veterinary Medical Colleges also announced it was establishing a working group to focus on strategies, such as scholarships or faculty and student exchange programs, to improve outreach and collaboration with minority-serving institutions. The association is in the process of naming and defining the strategy of the group.
As previously reported by JAVMA News, a number of historically Black colleges and universities offer veterinary- or animal-related undergraduate degrees.
The AAVMC has been leading diversity efforts over the past 15 years with such initiatives as DiVersity Matters, its Diversity and Inclusion on Air podcast, and, most recently, Diversity Community Reads, a book club designed to facilitate learning around DEI issues in veterinary education.
Lisa Greenhill, EdD, senior director for institutional research and diversity at the AAVMC, said in September that the applicant pool is increasingly diverse, but there is still a lot of progress to be made.
During its Pet Healthcare Industry Summit, held virtually Sept. 14-15, Banfield Pet Hospital announced the creation of the Diversify Veterinary Medicine Coalition and the launch of a $125,000 gift to Tuskegee University College of Veterinary Medicine for the Banfield and Royal Canin Student Support Fund.
The coalition will focus on increasing diversity, equity, and inclusion among veterinary professionals. The scholarship will support Tuskegee veterinary students who have financial need. Tuskegee is a historically Black university and, according to the veterinary college, has educated more than 70% of the nations African American veterinarians.
Brian Garish, president at Banfield, said the company is shifting to being activists and taking action.
Banfield is committed to partnering with the veterinary industry to ensure the talent pipeline grows and diversifies to meet the evolving needs of pets, people, and society, Garish said in a press release.
Members of the coalition include Boehringer Ingelheim, Mars Veterinary Health, Royal Canin, Antech Diagnostics, the National Association of Black Veterinarians, the Association of American Veterinary Medical Colleges, and the Multicultural VMA. The coalition will complement the work of the commission being established by the AVMA, the AAVMC, the Veterinary Medical Association Executives, and others that will aim to drive equity, diversity, and inclusion across the profession.
Banfield is also pledging to make a $1 million investment in DEI efforts to increase representation, training, and support to improve the diversity pipeline.
We are the least diverse of the health care professions, said Dr. Molly McAllister, chief medical officer at Banfield. There is no way to sugarcoat this. We are at a tipping point.
A panel discussion during the Pet Healthcare Industry Summit focused on diversity, equity, and inclusion in veterinary medicine.
Dr. Ruby Perry, dean of Tuskegees veterinary college, said if a person is going to make an impact, she has to have courage.
Your courage will inspire action, she said. This conversation should not end here. This is not a moment. This is a movement to change society.
Every child should be able to see themselves among veterinarians, said Dr. Sandra San Miguel, founder and leader of the League of VetaHumanz from Purdue University College of Veterinary Medicine. The League of VetaHumanz program defines a VetaHuman as a human being with superpowers who protects animal and public health; synonym: veterinarian.
The program will focus on expanding role models to reach children who may not have veterinarians in their lives by creating a global and inclusive Veterinary Superhero League. VetaHumanz in academia, practice, research, government, and industry engage K-12 students by creating and delivering resources focused on science, technology, engineering, and math.
VetaHumanz builds on the This is How We Role program, which started 11 years ago. Some of the resources include the SuperPower Packs, which are in development and will contain a game focused on veterinary medicine; collectible cards of role models; a cape; and a shield.
Get more information about VetaHumanz.
Dr. Willie Reed, dean of Purdues veterinary college, also spoke during the panel at the Pet Healthcare Industry Summit. He said there is still work to be done.
We have made some progress, but we have so far yet to go. It cant just be the colleges doing this alone, Dr. Reed said. We need the entire veterinary profession to say this is not acceptable and we have to do better.
Correction: An earlier version of this article misstated the title of Brian Garish.
Go here to read the rest:
Veterinary organizations take diversity- and equity-related action - American Veterinary Medical Association
Veterinary Medicine Market Forecast 2020-2026
The Global Veterinary Medicine Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.
The report consists of trends that are anticipated to impact the growth of the Veterinary Medicine Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.
Get a PDF Copy of the Sample Report for free @ https://dataintelo.com/request-sample/?reportId=88548
The Report Covers the Following Companies:Boehringer IngelheimZoetisElanco Animal HealthBayer Animal HealthMerck Animal HealthVirbacDechra Veterinary ProductsCevaVetoquinolMeijiOuro Fino SaudeAnimalcare GroupParnell
By Types:OralInjectionOther
By Applications:Companion AnimalsLivestock Animals
Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.
By Regions:
Grab Your Report at an Impressive Discount! Please visit https://dataintelo.com/ask-for-discount/?reportId=88548
Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026
Important Facts about Veterinary Medicine Market Report:
What Our Report Offers:
Make an Inquiry of This Report @ https://dataintelo.com/enquiry-before-buying/?reportId=88548
About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.
Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com
Read the original post:
Veterinary Medicine Market (2020-2026) | Where Should Participant Focus To Gain Maximum ROI | Exclusive Report By DataIntelo - PRnews Leader
SNOQUALMIE, Wash., Oct. 13, 2020 /PRNewswire/ -- The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference Oct. 2 Oct 4 in a virtual, online platform, a change from the usual face-to-face meetings that took place pre-pandemic. Veterinarians, veterinary staff, and citizens were honored at WSVMA's award ceremonies on Friday, Oct. 2.
Dr. Brian Joseph, State Veterinarian at the Washington State Dept. of Agriculture, Olympia, WA, received the 2020 Veterinarian of the Year Award. The award is presented in recognition of an outstanding career in veterinary medicine and contributions made to their practice, stakeholders, and other service directly benefitting their community. Dr. Joseph is an exceptional and compassionate leader with an esteemed career in many facets of veterinary medicine, including aquatic and zoo medicine, agriculture, and as a leader in the U.S. Army Reserve Veterinary Corp. His depth of knowledge combined with his incomparable character has inspired the men and women under his leadership, led to the improved health of animals and the public, and has positively impacted the many communities he's served. As Washington's "State Veterinarian," he not only works to prevent animal disease and protect food safety, but inspires many within the veterinary community and the public.
Dr. Ron Wohrle, Washington's former State Public Health Veterinarian from Puyallup, WA, received the 2020 Distinguished Achievement award. The award was presented to recognize Dr. Wohrle's dedication and outstanding contributions not only to veterinary medicine but to the citizens of Washington and beyond through his work in environmental public health. His expertise and wisdom combined with his unwavering commitment to One Health has created a safer Washington for animals and people in the protection from zoonotic diseases such as rabies, leptospirosis, and many others. His leadership in combatting antimicrobial resistance led to statewide efforts that brought together health experts from across professions and raised awareness in order to protect Washington citizens, animals and the environment against drug-resistant infections.
Dr. Katie Kuehl, Clinical Instructor and Medical Director for the Shelter Medicine program and the Seattle One Health Clinic in Seattle at Washington State University College of Veterinary Medicine was awarded the 2020 WSU Faculty Member of the Year Award. Her professionalism, enthusiasm, and passion have created rewarding and critical learning experiences for veterinary students, and her work with animals owned by people experiencing homelessness has created a healthier community in and around Seattle.
Benita Altier, LVT, VTS (Dentistry), Easton, WA, licensed veterinary technician and dentistry specialist technician at Pawsitive Dental Education, LLC, received the 2020 Distinguished Veterinary Staff Award. Ms. Altier is recognized for her exceptional leadership in veterinary dentistry and radiography through her education of veterinary technicians, which has led to the improved care of cats and dogs.
Ann Graves, Director of the Seattle Animal Shelter, was presented the 2020 WSVMA Humane Animal Welfare Award in recognition of her advancement of animal welfare and community wellbeing through her extraordinary career within animal welfare and shelter organizations.
Dr. Shlomo Frieman and Allon Freiman, from Petriage in Bellevue, WA, received the 2020 Allied Industry Partner Award in recognition of their exceptional service to the veterinary profession through their online tele-triage service that connects pet parents with their veterinarian and helps them assess the urgency for veterinary care.
The WSVMA is a statewide, not-for-profit, professional organization for the benefit of veterinary medicine. The WSVMA has over 1,900 members, representing veterinarians, veterinary students and a broad spectrum of veterinary practice. The Association's mission is to "advance the cause of veterinary medicine to better the lives of those touched by it." Visit the WSVMA Web site, http://www.wsvma.org, to learn more about the association, veterinary medicine, and animal care.
Read more from the original source:
Washington State's Veterinary Association Announces Annual Award Winners - Daily Record-News
Event
Virtual annual meeting, July 30-Aug. 6
Lasher-Bottorff AwardDr. Eric Gingerich (Purdue 77), Zionsville, Indiana, in recognition of an avian diagnostician or technical service veterinarian who has made important contributions to the poultry health program in North America over the past 10 years. Dr. Gingerich serves as a technical poultry specialist for Diamond V. He is a diplomate of the American College of Poultry Veterinarians.
Phibro Animal Health Excellence in Poultry ResearchMark Jackwood, PhD, Watkinsville, Georgia, for sustained excellence in poultry disease and health for 20 years or more. Dr. Jackwood earned his doctorate in 1985 from The Ohio State University. He is head of the Department of Population Health and the Poultry Diagnostic and Research Center at the University of Georgia College of Veterinary Medicine. Dr. Jackwood also serves as the J.R. Glisson Professor of Avian Medicine at the veterinary college. He is known for his expertise on infectious bronchitis virus, Bordetella avium rhinotracheitis of turkeys, mycoplasmosis, infectious laryngotracheitis, Newcastle disease, Pasteurella multocida, and infectious bursal disease.
Outstanding Field Case and/or Diagnostic Report AwardDr. Geoffrey Lossie (Purdue 14), Lafayette, Indiana. A diplomate of the ACPV, Dr. Lossie is a clinical assistant professor at Purdue University College of Veterinary Medicine, where he also serves as an avian pathology diagnostician at the Indiana Animal Disease Diagnostic Laboratory.
P.P. Levine AwardDr. John R. Dunn (Michigan State 03), Athens, Georgia, won this award, presented to the senior author of the best paper published in the journal Avian Diseases. Dr. Dunn is a research leader with the U.S. Department of Agriculture Agricultural Research Services National Poultry Research Center.
AAAP Special Service Award and Excellence in Mentorship AwardDr. Mark Bland (Oregon State 87), Napa, California. A past president of the AAAP, Dr. Bland serves as a poultry veterinarian consultant for Cutler Associates International. He was recognized for his dedication to the poultry industry and for his mentorship of students through the associations preceptorship program.
Reed Rumsey Student AwardDrs. Ana da Silva, Davis, California, and Amir Ghorbani, Wooster, Ohio. Dr. da Silva won in the category of clinical research in avian medicine. She received her veterinary degree in 2010 from Federal University of Parana in Brazil. Dr. Ghorbani won in the category of basic research in avian medicine. He received his veterinary degree in 2012 from Islamic Azad University, Karaj Branch, in Iran.
A.S. Rosenwald Student Poster AwardDr. Victor Palomino-Tapia, Calgary, Alberta, won in the category of applied research. Dr. Palomino-Tapia received his veterinary degree in 2007 from National University of San Marcos in Peru. Dr. Mohammadreza Ehsan, Athens, Georgia, won in the category of basic research. Dr. Ehsan received his veterinary degree in 2013 from Islamic Azad University, Garmsar Branch, in Iran and earned his doctorate in bordetellosis in 2017 from the University of Tehran in Iran.
Hall of Honor InducteesDrs. Lisa Nolan (Georgia 88), Watkinsville, Georgia; Patricia Dunn (Wisconsin 89), Port Matilda, Pennsylvania; and Patricia Wakenell (Michigan State 77), West Lafayette, Indiana. Dr. Nolan earned her doctorate in 1992 in medical microbiology from the University of Georgia. She serves as the Georgia Athletics Association Distinguished Professor and dean of the University of Georgia College of Veterinary Medicine. A diplomate of the ACPV, Dr. Dunn serves as an avian diagnostic pathologist and field investigator with the Animal Diagnostic Laboratory in the Department of Veterinary and Biomedical Sciences at Pennsylvania State University College of Agricultural Sciences. Dr. Wakenell earned her doctorate in 1985 from Michigan State University. A diplomate of the American College of Veterinary Pathologists, she is a professor emerita of poultry medicine at Purdue University, where she was head of avian diagnostics at the Animal Disease Diagnostic Laboratory from 2008-19.
AAAP Life Member AwardDr. John Glisson (Georgia 80), Watkinsville, Georgia, in recognition of his outstanding service to the poultry industry. Dr. Glisson earned his doctorate in medical microbiology in 1985 from the University of Georgia. He spent his academic career at the university and served as vice president of research at the U.S. Poultry & Egg Association prior to retirement.
Dr. David Frame, Ephraim, Utah, president; Dr. Louise Dufour-Zavala, Gainesville, Georgia, president-elect; Dr. Eric Jensen, Huntsville, Alabama, immediate past president; Dr. Suzanne Dougherty, Elkmont, Alabama, executive vice president; Dr. Holly Sellers, Athens, Georgia, associate director; Kelly Hewitt, Ames, Iowa, student director; and directorsDrs. K.A. Ton Schat, Ithaca, New York; Samuel Christenberry, Cullman, Alabama; Michelle Kromm, Wilmar, Minnesota; Julie Helm, Columbia, South Carolina; Karen Grogan, Dacula, Georgia; and Rosemary Marusak, Chetek, Wisconsin
Follow this link:
American Association of Avian Pathologists - American Veterinary Medical Association
"Pet cancer is the #1 disease-related killer of dogs and cats, and a devastating diagnosis for pet parents who cannot afford treatment for their pets. With all the strides being made in the veterinary oncology field increasing treatment options for our pets, our goal is to make these lifesaving treatments available to more pets and their pet parents," said Susanne Kogut, president of the Petco Foundation. "University treatment funds to support pet cancer did not universally exist prior to our creation of this support. Not only are these funds changing the lives of pets and pet parents, but it is improving the outlook for our veterinarian professionals who can help even more pets when costs might otherwise preclude such treatment."
The National Cancer Institute Center for Cancer Research estimates 6 million dogs and nearly the same number of cats are impacted by cancer each year.
"Blue Buffalo has been committed to fighting pet cancer since our inception," said Danielle Donegan, Manager of Strategic Partnerships & Retail Activation at Blue Buffalo. "We are proud of the collaborative efforts together with Petco and the Petco Foundation to raise funds, increase awareness and help pet parents and their pets in the fight against pet cancer."
On Wednesday, Oct. 14, representatives from Petco, Petco Foundation, and Blue Buffalo toured the Louisiana State University School of Veterinary Medicine's Oncology Center and discussed the continued need for this lifesaving support. At the conclusion, Kogut and Petco CEO Ron Coughlin presented LSU School of Veterinary Medicine with $75,000 for the continuation of the Petco Foundation and Blue Buffalo pet cancer treatment fund. LSU is one of 11 universities to be awarded an additional $75,000 this fall including: Colorado State University Foundation, Cornell Veterinary College, North Carolina Veterinary Medical Foundation, Ohio State University Foundation, Texas A&M University, UC Davis School of Veterinary Medicine, University of Florida Foundation, University of Pennsylvania, University of Tennessee Foundation and University of Wisconsin Foundation.
The Petco Foundation, in partnership with Blue Buffalo, are continuing their annual campaign to raise funds for pet cancer but expanding efforts to include raising funds for other critical pet health care needs. According to a studyby theUniversity of Tennessee's Access to Veterinary Care, an estimated 29 million dogs and cats live in households that rely on the federal Supplemental Nutrition Assistance Program (SNAP). Seventy-four percent ofpetowners reported not being able to afford sick care, with middle class participants as likely to cite financial barriers as lower-income participants. From now through October 25, the public can help pets receive treatment for pet cancer and other lifesaving care by donating at Petco or online at petcofoundation.org/pethealth.
To learn more about the Petco Foundation and its efforts to provide lifesaving treatment to pets, visit petcofoundation.org/pethealth and follow along on Facebook, Twitterand Instagram.
About the Petco Foundation At the Petco Foundation, we believe that every animal deserves to live its best life.Since 1999, we've invested more than $280 million in lifesaving animal welfare work to make that happen. With our more than 4,000 animal welfare partners, we inspire and empower communities to make a difference by investing in adoption and medical care programs, spay and neuter services, pet cancer research, service and therapy animals, and numerous other lifesaving initiatives. We also partner with Petco stores and animal welfare organizations across the country to increase pet adoptions. So far, we've helped more than 6.5 million pets find their new loving families, and we're just getting started. Visit petcofoundation.org to learn more about how you can get involved.
About Blue Buffalo Company Based in Wilton, CT, Blue Buffalo is the nation's leading natural pet food company, and provides natural foods and treats for dogs and cats under its BLUE Life Protection Formula, BLUE Wilderness, BLUE Basics, BLUE Freedom and BLUE Natural Veterinary Diet lines. Paying tribute to its founding mission, the company is a leading sponsor of pet cancer awareness and critical studies of pet cancer, health, treatment and nutrition at top veterinary medical schools across the United States. For more information about Blue Buffalo, visit http://www.BlueBuffalo.com.
Contact: Jennifer Perez, Petco Foundation, [emailprotected]
SOURCE Petco Foundation
Read this article:
Petco Foundation Continues Commitment to Fund Pet Cancer Treatment at Top US Universities and Expands Initiative to Support Other Critical Pet Health...
Direct-to-consumer (DTC) pet brands and subscription services have been on the rise over the last year, and one takeaway from shoppers is a litany of ever increasing options when it comes to finding the best dog food for their dogs. And while a canine companion can generally help you unwind and relieve stress, whether youre pent up working from home or sheltering from Covid-19, youre probably spending more time together these days and you may be left wanting to reward them for their company or improving their health otherwise. One way to indulge your dog (and really anyone) is through elevating their food. Sundays, a direct-to-consumer dog food brand, claims to be healthier than kibble and easier to prepare than some of its human-grade food counterparts it aims to fill a void between the affordable dry dog food on one end and the high quality and high-priced elevated dog food on the other.
SKIP AHEAD Other DTC Brands
The DTC brand launched in early August, joining other newcomers in the dog food space this year like Tailored and Jinx, as well as older companies like Nom Nom and The Farmers Dog. If youre on the market for a new dog food or like to stay updated on your options, eyeing the many new ones available to you from bestsellers at Petsmart, Chewy, Petco, Amazon, Walmart and other major retailers to direct-to-consumer options there are some things youll want to consider. To help guide your shopping through some of those young brands, we consulted experts and veterinarians on what to know before buying food directly from a brand.
I like to joke that the reason Sundays exists is because a software engineer married a veterinarian.
Michael Waxman, Co-Founder and CEO, Sundays
I like to joke that the reason Sundays exists is because a software engineer married a veterinarian, said Michael Waxman, an engineer and the co-founder and CEO of Sundays, referencing his partner and wife Tory Waxman, VMD, the companys co-founder and chief veterinary officer. The duo says they created Sundays in order to offer pet owners an option between kibble and top-shelf dog food. We would do literally anything for our dogs except prepare their food for an hour or two, Waxman said, alluding to another value he hopes Sundays will offer: speed and simplicity.
The Sundays dog food formula is composed of more than 90 percent meat, for protein, as well as a variety of fruits, vegetables and natural oils for their respective antioxidants and digestive properties, among other nutrients. Air dried and shipped to your door, Sundays veers away from the need to can or refrigerate its elevated kibble.
That same air-drying procedure leaves Sundays with a jerky-like texture. According to the company, the food has been tested to meet both the Food and Drug Administration (FDA) standard of fit for human consumption, as well as similar standards from the Association of American Feed Control Officials (AAFCO). The food, made in a USDA-monitored kitchen, includes USDA beef composed of different beef parts: beef heart, beef liver and beef bone. Sundays also throws in grains and other ingredients for flavor and health benefits: quinoa, pumpkin, wild salmon oil, kale, turmeric and more. The brand notes its food is completely free of synthetics.
Although there is currently only one recipe, Waxman says that different dogs should consume it in different portions. To help you find the right amount for your dog, Sundays offers up a simple quiz, in which pet owners provide answers regarding their dogs age, breed and other factors. Additionally, Waxman says Sundays hopes to launch a second recipe later this year, but plans to stray from offering too many choices.
While DTC brands are on the rise, many veterinarians still see kibble as an important part of dogs diet. For dogs, the main benefit to being on a commercially-prepared dry dog food is that they are eating a complete and balanced diet, Kristin Neuhauser, DVM, of Noahs Ark Animal Clinic, previously told NBC News Shopping. Something to look out for when shopping for any dog food is that it meets nutrient standards set by organizations such as AAFCO. If not [complete and balanced] then theres vitamins and minerals that need to be added, said Joseph Wakshlag, DVM, a professor of Sections of Clinical Nutrition and Sports Medicine and Rehabilitation at the College of Veterinary Medicine at Cornell. I, as a veterinarian nutritionist, feel much more comfortable [knowing] a product has met AAFCO specifications. Still, the type of diet and dog food may vary from pet owner to pet owner depending on a variety of factors, from convenience and price to the ingredients used, their nutritional value and otherwise. To give you an idea of other DTC dog food brands out there, here some of the top options.
The Farmers Dog meals are formulated by the companys veterinarian nutritionists to meet AAFCO nutrition standards and include human-grade, USDA meat and vegetables. They are exempt from chicken or other meals, natural or artificial preservatives and dont include any kibble and come pre-made and pre-portioned. The beef option is made of USDA beef, sweet potato, lentils, kale and more. Although your dogs meal plan is determined by a quiz, The Farmers Dog also sells a Turkey, Chicken or Pork option.
Unlike some of the above DTC counterparts, Jinx offers kibble. The recipes are designed by a team of veterinary scientists and nutritionists, meet AAFCO standards and are third party tested. This Chicken/Brown Rice recipe also includes eggs, avocado, patented probiotics, grain and more. Youll also find other recipes, including Salmon/Brown Rice and Chicken/Sweet Potato. And since were all snacking more these days, check out their dog treats.
Nom Nom meals use only USDA-grade A proteins and vegetables, and are created by Justin Shmalberg, DVM to the nutritional levels established by AAFCO Food Nutrient Profiles, according to the company. The meals come in options for dogs or cats and, according to the company, ship cold, fresh and pre-portioned. The Beef Mash recipe includes beef, potatoes, eggs, carrots and more. Youll also find other flavors, including Chicken Chow, Pork Potluck and Turkey Fare. Plus, you can try a variety pack to see which option your pet gravitates to most.
Pet Plate meals meet AAFCO nutrition standards in terms of protein, fat, minerals, vitamins and more, and are formulated by Renee Streeter, DVM, DACVN, a veterinary nutritionist. The meals are human-grade, dont include artificial ingredients and are USDA-certified. According to the company, they are hot-sealed and flash frozen for safety and freshness. This beef option features ground beef, sweet potatoes, beef liver, carrots and more. You can also choose from a variety of flavors including Chompin Chicken, Lip Lickin Lamb and Tail Waggin Turkey.
Catch up on the latest from NBC News Shopping guides and recommendations and download the NBC News app for full coverage of the coronavirus outbreak
Shari Uyehara is a production coordinator and writer for NBC News Shopping
Follow this link:
DTC dog food brands are on the rise: What to know - NBC News
The lion had lymphoma, andTara Harrisonwas told there was nothing that could be done.
Harrison thought differently.
I said, OK, great. Lets treat him. Then I found out no one had ever done that, says Harrison. They said, Hes old. Hes lived his life. Just euthanize him. I thought, but why? Why?
That was Harrisons first major case working at a zoo. Fifteen years later, the experience continues to motivate the NC State College of Veterinary Medicine assistant professor. During her five years at the CVM, while treating a wide variety of exotic species from ferrets and bearded dragons to anteaters and porcupines, Harrison has been compiling a database of cancer cases seen in zoological medicine.
Harrison methodically tracks types of cancer, treatment plans and outcomes from data collected from private practices, zoos and other institutions. Its the only database of its kind in the world and already has hundreds of entries.
The database broadens scientific knowledge on cancers existing in zoological medicine, a broad term that covers exotic, nontraditional pets, animals under human care at zoos and those in the wild. Each case added to the database sheds much-needed light, faint or bright, on the cancers animals get and how they get them.
Refining an understanding of cancer in animals has tremendous potential to help treat cancer in humans, whose genetic makeup is vastly similar to other mammals. The cancer database is run in partnership with Ashley Zehnder, a former colleague of Harrisons at the University of California, Davis. Zehnder is the cofounder and the CEO of FaunaBio, a San Francisco-area company developing therapies based on comparative genomics to improve human and animal health.
When we have new students entering our exotic animal service rotation at the CVM, I tell them that I want to cure cancer, says Harrison. Its a lofty goal, obviously, but I think every little bit helps. If we understand cancer in other animals, understand the treatments and understand the genetics behind it, I think that will get us closer to it.
Harrisons focus is leading to even more groundbreaking work. In December, she was the only veterinarian on a research team that traveled to Kenya to investigate cancer in wild animals, a collaboration with the Kenya Wildlife Service and their mobile veterinary unit including KWS forensics director Moses Otiende, veterinarian Dominic Mijele, graduate student Samuel Omolo and Hastings Ozwara from the Institute of Primate Research, based in Nairobi.
The wildlife cancer study is led by a consortium of researchers working with the Arizona Cancer Evolution Center (ACE) at Arizona State University. It is funded by a supplemental and pilot grant from the National Institutes of Health and partly by the Wildlife Conservation Observatory Network.
The ACE research group that traveled to Kenya represents a multi-disciplinary and multi-institutional approach to addressing animal and human cancer.
Amy Boddy is an assistant professor of anthropology at the University of California, Santa Barbara. Lisa Abegglen is an assistant professor of pediatric hematology and oncology at the University of Utahs Huntsman Cancer Institute. Valerie Harris is a Ph.D. graduate student and Diego Mallo is a postdoctoral student, both at ASU, while Kathleen Noble is a laboratory specialist at the Huntsman Cancer Institute.
The group is currently analyzing cancer in wildlife data and a research paper is in the works. They hope to return to Kenya to continue to collect data in other wild species, says Harrison.
Cancer in wildlife has long been thought of as a disease of captivity, because animals dont live as long in the wild and perhaps dont live long enough to get cancer, says Harrison, who has a masters in veterinary epidemiology in addition to a DVM. Or cancer was seen in the wild as only being associated with toxic oil spills or pollution or viruses.
Its the groups first big foray into uncovering whats causing cancer in the wild, what kind of cancers are out there and how these cancers affect survival.
Cancer treatment for exotic pets and wild animal species has come a long way, even since Harrison worked with that first lion not-so long ago. As cancer treatment for pets such as dogs and cats have become commonplace and increasingly successful, zoological medicine has followed the lead. Since fewer exotic species were being seen by veterinarians in the past, cancer diagnosis and treatment often came too late if at all, says Harrison.
When we have new students entering our exotic animal service rotation, I tell them that I want to cure cancer, says Harrison. If we understand cancer in other animals, I think that will get us closer to it.
Now, more exotic pets are being seen for annual health exams, including at the NC State Veterinary Hospital. Large zoos and aquariums often have full-time veterinarians on staff, and they also often call veterinarians like Harrison for treatment consultations.
Though collecting cancer data from wildlife is challenging and most of Harrisons cancer database information comes from exotic pet cases and animals in zoos, the information already has potential to guide treatments for similar cancers in wildlife.
Cancer doesnt have to mean the end, says Harrison. As veterinarians, it doesnt have to mean you stop. This feels like a new beginning. We can do something about this, and we will.
Excerpt from:
Cancer database changes the game for exotic pets and wildlife - Jill Lopez
As one of the first two states in the United States to legalize cannabis, Colorado has been at the forefront of research. The Institute of Cannabis Research at Colorado State University Pueblo has just kicked off a series of virtual events during which researchers discuss their work, and where research is headed.
The first such webinar featured Stephanie McGrath, an associate professor of neurology and neurosurgery at the College of Veterinary Medicine and Biomedical Science at Colorado State University in Fort Collins. She focused her presentation on her work covering the use of cannabidiol (CBD) for dogs that have seizure disorders, and how glioma cancer cells in dogs respond to CBD treatment.
The next CU Pueblo research webinar will feature David Shurtleff, deputy director of the National Center of Complementary and Integrative Health, and will focus on the National Institute of Healths interest in cannabis research.
(Read Cannabis Wires previous coverage of research out of Baylor College of Medicine, within the Texas Medical Center, on the therapeutic potential of CBD for dogs experiencing pain from arthritis.)
Like many medical professionals, McGrath didnt enter medical school with a decision on which path shed like to pursue, but she eventually settled on neurology. McGrath referred to epilepsy in dogs, the most common neurologic disorder in canines, as an eye opener that hit home, because existing treatments seemed inadequate, she said.
Until you witness this, its really hard to appreciate what owners are going through, McGrath said, referencing dogs undergoing grand mal seizures. But when youre looking at this dogs eyes and youre looking into the eyes of this family that are going through this very emotional, very traumatic and violent disease, she said, you connect to the real emotional aspect of it like this.
While McGrath completed her residency in Colorado, legal adult use cannabis sales were taking off. McGrath referenced Charlotte Figi, a young girl whose family moved her to Colorado for access to CBD to treat her seizures. (Figi, who became internationally known for helping to catalyze the CBD-as-medicine movement, died in April). Watching the Sanjay Gupta special on Figi and CBD on CNN, McGrath wondered if CBD might have the same seizure-reducing effects on dogs.
I went through school knowing marijuana is toxic for dogs. Its terrible. Dont use it. Stay away from it. We see marijuana toxicosis in our emergency rooms, McGrath said.
McGrath began her research on CBD at CSU under the 2014 Farm Bill, which allowed for states to launch hemp pilot programs. Hemp is abundant in CBD. But, she said, her work became easier when lawmakers passed the 2018 Farm Bill, which removed hemp, defined as cannabis plants containing .3% THC or less, from the list of controlled substances.
I think its made it a lot easier for collaborators and other researchers and scientists to start exploring cannabis at their institutions as well, which is great, McGrath said. She added that her own research began, in some senses at ground zero, because there were so few studies on dogs and CBD that could serve as a starting point for additional work.
We had essentially no foundation for using this drug despite it being around forever. And so we had a lot of questions about bioavailability, whether this drug would even be absorbed, she said.
McGrath started with a pharmacokinetic study during which 30 dogs were given three different CBD formulations. The dogs received a six-week course of two doses daily. The beagles used for the study were research animals that were purpose-bred for pharmacokinetic studies and that are adopted out once they reach middle age. Researchers looked for safety, drug tolerance, and any major adverse effects.
It was very encouraging that at least we had a foundation, somewhere to go with this, McGrath said, referencing that the oral preparations were at least measurable in the dogs blood streams. Fortunately for adverse events, those were also fairly well-tolerated, she said. The only major side effect was diarrhea, which was transient, but it did occur in all dogs at all dosages at various time points. There also was an elevation in one of the liver enzymes, alkaline phosphatase, and while the researchers didnt have concerns related to short-term liver toxicity concerns, that was definitely something we noted and wanted to continue to monitor.
Overall, McGrath said, she felt that this studys results would allow her to proceed to clinical trials in client-owned animals, starting with epilepsy. Her first effort was on the short-term effect of CBD on seizure frequency in dogs suffering from poorly-controlled idiopathic epilepsy. A total of sixteen dogs participated in this study, a limitation with such a small cohort, with nine in the treatment group and seven in the control group. All of these dogs had a confirmed diagnosis of idiopathic epilepsy, and they all had to remain on their standard anticonvulsant treatment during the three-month study. Researchers then added either CBD to the treatment regimen, or a placebo.
We did see a significant reduction in seizure frequency in the treatment group as compared with the control group, McGrath said. But, she added, when they looked at responders, a common way of recording antiepileptic drug efficacy, they wanted the dogs to have at least a 50 percent reduction in seizure activity, which didnt happen.
We concluded from this study that, although we did get some encouraging results, theres still a lot more work to be done, she said.
McGrath said the most interesting part of the study, to her, was that she saw a significant correlation between plasma level and seizure change.
As the dogs, that for whatever reason, metabolize the drug in such a way that they reached higher plasma levels, they actually had a further decrease in seizure activity than dogs that never reach that level. And so seeing that correlation really gave me a lot of hope that if we can get more dogs sort of across the arbitrary threshold, that we may be able to see better, more positive results, McGrath said.
McGraths next clinical study was funded by the American Kennel Club Canine Health Foundation, and was much larger, with 60 dogs. It was a prospective double blind, placebo-controlled crossover study. The dogs in the study received either CBD or placebo in the first phase, and then CBD or placebo for the second phase.
It gives us a bit more of a powerful study because each dog is able to be compared to itself as well as the treatment group and the control group, she said. For this study, CBG was also added, and doses were increased in an effort to get more dogs into a higher-level plasma range. During the course of this study, Epidiolex, a CBD-based cannabis plant extract, was approved by the Food and Drug Administration, which McGrath and her team started using as part of the study.
Spoiler alert: I do not have results of the study yet, McGrath said. She and her team wrapped up enrollment last month, and the last dog is expected to finish in March, allowing them to publish results sometime next year.
Overall, we didnt see any clinical signs that were of concern. We are also measuring antiepileptic drug levels throughout the studies. So we are going to also assess whether CBD has any effect on raising or lowering the antiepileptic drug levels as well, she said.
Go here to see the original:
Colorado: Institute of Cannabis Research Series Launches With CBD and Dogs - Cannabis Wire